---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016659"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:30:53.757659+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology stockholders approve all proposals at 2025 annual meeting

## Summary
- Seven director nominees elected, including CEO Mark Erlander, with between 20.4M and 21.2M votes each.
- Ratification of BDO USA as independent auditor for FY2025: 36.3M for, 1.2M against.
- Amendment to 2021 Equity Incentive Plan approved (16.9M for, 5.0M against); shares available increased to 12.15M.
- Advisory say-on-pay vote on named executive officer compensation approved (18.9M for, 2.6M against).

## SEC filing metadata
- accession: 0001641172-25-016659
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000164117225016659/0001641172-25-016659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000164117225016659/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016659
- JSON: https://secwatch.observer/filing/0001641172-25-016659.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.